Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 14INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Angiogenesis Inhibitors × Clear all
NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

NCT01204749 2016-12-15

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Amgen

Phase 3 Completed
919 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00093873 2013-05-15

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡